atabecestat
Jump to navigation
Jump to search
Contraindications
- treatment of preclinical Alzheimer's disease (no benefit)
Adverse effects
- dose-related cognitive worsening as early as 3 months*
* evidence of reversibility after 6 months off treatment[2]
Mechanism of action
- beta-secretase inhibitor
More general terms
References
- ↑ Henley D, Raghavan N, Sperling R et al Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease. N Engl J Med 2019; 380:1483-1485. April 11. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30970197
- ↑ 2.0 2.1 Sperling R, Henley D, Aisen PS et al Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease, A Truncated Randomized Phase 2b/3 Clinical Trial. JAMA Neurol. Published online January 19, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33464300 https://jamanetwork.com/journals/jamaneurology/fullarticle/2774863